NASDAQ:AGLE - Aeglea Bio Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.62 +0.90 (+9.26 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$9.72
Today's Range$9.69 - $10.94
52-Week Range$2.81 - $11.35
Volume211,700 shs
Average Volume156,334 shs
Market Capitalization$216.18 million
P/E Ratio-5.90
Dividend YieldN/A
Beta-0.08

About Aeglea Bio Therapeutics (NASDAQ:AGLE)

Aeglea Bio Therapeutics logoAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine, as well as AEB4104, an engineered human enzyme that targets the reduction of elevated levels of the amino acid homocysteine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Receive AGLE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGLE
CUSIPN/A
Phone512-942-2935

Debt

Debt-to-Equity RatioN/A
Current Ratio8.48
Quick Ratio8.48

Price-To-Earnings

Trailing P/E Ratio-5.90
Forward P/E Ratio-6.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.20 million
Price / Sales44.64
Cash FlowN/A
Price / CashN/A
Book Value$2.01 per share
Price / Book5.28

Profitability

EPS (Most Recent Fiscal Year)($1.80)
Net Income$-27,230,000.00
Net Margins-507.82%
Return on Equity-54.83%
Return on Assets-49.87%

Miscellaneous

Employees43
Outstanding Shares21,860,000

Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions

What is Aeglea Bio Therapeutics' stock symbol?

Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."

How were Aeglea Bio Therapeutics' earnings last quarter?

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.05. The biotechnology company had revenue of $1.51 million for the quarter. Aeglea Bio Therapeutics had a negative return on equity of 54.83% and a negative net margin of 507.82%. View Aeglea Bio Therapeutics' Earnings History.

What price target have analysts set for AGLE?

3 Wall Street analysts have issued 12 month price targets for Aeglea Bio Therapeutics' stock. Their predictions range from $18.00 to $37.00. On average, they expect Aeglea Bio Therapeutics' stock price to reach $25.00 in the next twelve months. View Analyst Ratings for Aeglea Bio Therapeutics.

Who are some of Aeglea Bio Therapeutics' key competitors?

Who are Aeglea Bio Therapeutics' key executives?

Aeglea Bio Therapeutics' management team includes the folowing people:
  • Dr. Anthony G. Quinn, Interim CEO & Director (Age 56)
  • Prof. George Georgiou Ph.D., Co-Founder and Director (Age 59)
  • Mr. Charles N. York II, M.B.A., Chief Financial Officer and VP (Age 41)
  • Dr. Scott W. Rowlinson Ph.D., VP of Research (Age 50)
  • Dr. Leslie Sloan Ph.D., Sr. VP of Operations

When did Aeglea Bio Therapeutics IPO?

(AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

Has Aeglea Bio Therapeutics been receiving favorable news coverage?

Media coverage about AGLE stock has been trending very positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aeglea Bio Therapeutics earned a media sentiment score of 0.50 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 41.79 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Aeglea Bio Therapeutics' major shareholders?

Aeglea Bio Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include NOVARTIS BIOVENTURES LTD (9.80%), Dimensional Fund Advisors LP (0.42%), Millennium Management LLC (0.34%), JPMorgan Chase & Co. (0.30%), Blair William & Co. IL (0.12%) and UBS Group AG (0.11%). Company insiders that own Aeglea Bio Therapeutics stock include Anthony G Quinn, Bioventures Ltd Novartis, Charles N York II and Orbimed Advisors Llc. View Institutional Ownership Trends for Aeglea Bio Therapeutics.

Which major investors are buying Aeglea Bio Therapeutics stock?

AGLE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., UBS Group AG, A.R.T. Advisors LLC, Blair William & Co. IL, Stanley Laman Group Ltd. and Spark Investment Management LLC. Company insiders that have bought Aeglea Bio Therapeutics stock in the last two years include Anthony G Quinn, Charles N York II and Orbimed Advisors Llc. View Insider Buying and Selling for Aeglea Bio Therapeutics.

How do I buy shares of Aeglea Bio Therapeutics?

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aeglea Bio Therapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $10.62.

How big of a company is Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics has a market capitalization of $216.18 million and generates $5.20 million in revenue each year. The biotechnology company earns $-27,230,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Aeglea Bio Therapeutics employs 43 workers across the globe.

How can I contact Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]


MarketBeat Community Rating for Aeglea Bio Therapeutics (AGLE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote "Outperform" if you believe AGLE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aeglea Bio Therapeutics (NASDAQ:AGLE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Aeglea Bio Therapeutics in the last 12 months. Their average twelve-month price target is $25.00, suggesting that the stock has a possible upside of 135.40%. The high price target for AGLE is $37.00 and the low price target for AGLE is $18.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.00$25.00N/AN/A
Price Target Upside: 135.40% upside216.46% upsideN/AN/A

Aeglea Bio Therapeutics (NASDAQ:AGLE) Consensus Price Target History

Price Target History for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Aeglea Bio Therapeutics (NASDAQ:AGLE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$37.00HighView Rating Details
4/13/2018Needham & Company LLCBoost Price TargetBuy$20.00HighView Rating Details
3/14/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$18.00MediumView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Aeglea Bio Therapeutics (NASDAQ:AGLE) Earnings History and Estimates Chart

Earnings by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Aeglea Bio Therapeutics (NASDAQ:AGLE) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.67 EPS
Next Year EPS Consensus Estimate: $-3.57 EPS

Aeglea Bio Therapeutics (NASDAQ AGLE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.4430)($0.49)$1.51 millionViewN/AView Earnings Details
3/13/2018Q4 2017($0.38)$1.48 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.55)($0.48)$1.26 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.59)($0.47)$1.48 millionViewN/AView Earnings Details
5/9/20173/31/2017($0.47)($0.47)$0.98 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.41)$1.25 millionViewN/AView Earnings Details
11/9/20169/30/2016($0.54)($0.47)$1.15 millionViewN/AView Earnings Details
8/9/2016Q2 2016($0.43)($0.46)$1.37 millionViewN/AView Earnings Details
5/19/2016Q1 2016($0.42)($7.10)$0.86 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aeglea Bio Therapeutics (NASDAQ:AGLE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aeglea Bio Therapeutics (NASDAQ AGLE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.00%
Institutional Ownership Percentage: 37.65%
Insider Trading History for Aeglea Bio Therapeutics (NASDAQ:AGLE)
Institutional Ownership by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Aeglea Bio Therapeutics (NASDAQ AGLE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018Bioventures Ltd NovartisMajor ShareholderSell73,955$10.12$748,424.60View SEC Filing  
5/7/2018Bioventures Ltd NovartisMajor ShareholderSell15,548$10.11$157,190.28View SEC Filing  
12/8/2017Anthony G QuinnCEOBuy8,288$4.96$41,108.4832,009View SEC Filing  
12/6/2017Anthony G QuinnCEOBuy4,888$4.92$24,048.9632,009View SEC Filing  
12/5/2017Charles N York IICFOBuy25,959$4.48$116,296.3210,828View SEC Filing  
12/4/2017Anthony G QuinnDirectorBuy7,956$4.98$39,620.8814,100View SEC Filing  
12/1/2017Anthony G QuinnDirectorBuy4,100$4.53$18,573.0014,100View SEC Filing  
12/1/2017Charles N York IICFOBuy6,500$4.59$29,835.0010,828View SEC Filing  
2/21/2017Orbimed Advisors LlcMajor ShareholderBuy109,300$5.16$563,988.00View SEC Filing  
4/12/2016Anthony QuinnDirectorBuy10,000$10.00$100,000.0010,000View SEC Filing  
4/12/2016Bioventures Ltd NovartisMajor ShareholderBuy300,000$10.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aeglea Bio Therapeutics (NASDAQ AGLE) News Headlines

Source:
DateHeadline
Aeglea Bio Therapeutics Inc (AGLE) Given Average Recommendation of "Buy" by BrokeragesAeglea Bio Therapeutics Inc (AGLE) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 3:36 AM
Aeglea Bio Therapeutics (AGLE) Stock Rating Upgraded by Zacks Investment ResearchAeglea Bio Therapeutics (AGLE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 15 at 4:59 PM
Aeglea BioTherapeutics to Present at UBS Global Healthcare ConferenceAeglea BioTherapeutics to Present at UBS Global Healthcare Conference
finance.yahoo.com - May 15 at 9:06 AM
Bioventures Ltd Novartis Sells 73,955 Shares of Aeglea Bio Therapeutics Inc (AGLE) StockBioventures Ltd Novartis Sells 73,955 Shares of Aeglea Bio Therapeutics Inc (AGLE) Stock
www.americanbankingnews.com - May 11 at 7:41 PM
Aeglea Bio Therapeutics Inc (AGLE) Expected to Post Earnings of -$0.44 Per ShareAeglea Bio Therapeutics Inc (AGLE) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - May 9 at 5:28 PM
Insider Selling: Aeglea Bio Therapeutics Inc (AGLE) Major Shareholder Sells 15,548 Shares of StockInsider Selling: Aeglea Bio Therapeutics Inc (AGLE) Major Shareholder Sells 15,548 Shares of Stock
www.americanbankingnews.com - May 9 at 4:23 PM
Aeglea Bio Therapeutics (AGLE) Posts  Earnings ResultsAeglea Bio Therapeutics (AGLE) Posts Earnings Results
www.americanbankingnews.com - May 9 at 3:34 PM
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial ResultsAeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 8:47 AM
Aeglea: 1Q Earnings SnapshotAeglea: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:47 AM
Aeglea Bio Therapeutics (AGLE) Raised to "Hold" at ValuEngineAeglea Bio Therapeutics (AGLE) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 4 at 3:34 PM
Aeglea Bio Therapeutics Inc (AGLE) Given Consensus Recommendation of "Hold" by BrokeragesAeglea Bio Therapeutics Inc (AGLE) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 24 at 9:22 AM
Evercore ISI Initiates Coverage on Aeglea Bio Therapeutics (AGLE)Evercore ISI Initiates Coverage on Aeglea Bio Therapeutics (AGLE)
www.americanbankingnews.com - April 24 at 8:51 AM
Zacks: Analysts Anticipate Aeglea Bio Therapeutics Inc (AGLE) to Announce -$0.54 Earnings Per ShareZacks: Analysts Anticipate Aeglea Bio Therapeutics Inc (AGLE) to Announce -$0.54 Earnings Per Share
www.americanbankingnews.com - April 22 at 9:10 AM
Aeglea BioTherapeutics Prices Public Offering of Common StockAeglea BioTherapeutics Prices Public Offering of Common Stock
finance.yahoo.com - April 19 at 8:46 AM
Aeglea BioTherapeutics Announces Proposed Public Offering of Common StockAeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 17 at 5:28 PM
 Aeglea Bio Therapeutics Inc (AGLE) Receives Consensus Rating of "Strong Buy" from Brokerages Aeglea Bio Therapeutics Inc (AGLE) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - April 16 at 9:25 AM
Needham & Company LLC Raises Aeglea Bio Therapeutics (AGLE) Price Target to $20.00Needham & Company LLC Raises Aeglea Bio Therapeutics (AGLE) Price Target to $20.00
www.americanbankingnews.com - April 13 at 11:01 AM
 Brokerages Anticipate Aeglea Bio Therapeutics Inc (AGLE) Will Post Earnings of -$0.54 Per Share Brokerages Anticipate Aeglea Bio Therapeutics Inc (AGLE) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 5 at 12:24 PM
Aeglea BioTherapeutics (AGLE) to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at AACRAeglea BioTherapeutics (AGLE) to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at AACR
www.streetinsider.com - April 5 at 10:50 AM
Aeglea Initiates Lung Cancer Combination Study With KeytrudaAeglea Initiates Lung Cancer Combination Study With Keytruda
finance.yahoo.com - April 3 at 5:05 PM
Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics MeetingAeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting
finance.yahoo.com - April 3 at 8:56 AM
Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination TrialsAeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
finance.yahoo.com - April 2 at 5:03 PM
Edited Transcript of AGLE earnings conference call or presentation 13-Mar-18 12:00pm GMTEdited Transcript of AGLE earnings conference call or presentation 13-Mar-18 12:00pm GMT
finance.yahoo.com - April 2 at 9:13 AM
Zacks: Aeglea Bio Therapeutics Inc (AGLE) Given Average Recommendation of "Strong Buy" by BrokeragesZacks: Aeglea Bio Therapeutics Inc (AGLE) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 1 at 3:10 AM
Aeglea Bio Therapeutics (AGLE) Rating Lowered to Hold at Zacks Investment ResearchAeglea Bio Therapeutics (AGLE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 9:04 PM
Aeglea BioTherapeutics Appoints Dr. Ivana Magovčević-Liebisch to Board of DirectorsAeglea BioTherapeutics Appoints Dr. Ivana Magovčević-Liebisch to Board of Directors
finance.yahoo.com - March 26 at 9:00 AM
Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare ConferenceAeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 20 at 9:02 AM
Aeglea Bio Therapeutics Inc (AGLE) Expected to Post Earnings of -$0.54 Per ShareAeglea Bio Therapeutics Inc (AGLE) Expected to Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - March 19 at 11:49 AM
 Aeglea Bio Therapeutics Inc (AGLE) Receives Consensus Recommendation of "Buy" from Brokerages Aeglea Bio Therapeutics Inc (AGLE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 16 at 3:18 PM
Want To Invest In Aeglea Biotherapeutics Inc (NASDAQ:AGLE)? Here’s How It Performed LatelyWant To Invest In Aeglea Biotherapeutics Inc (NASDAQ:AGLE)? Here’s How It Performed Lately
finance.yahoo.com - March 16 at 8:54 AM
Aeglea BioTherapeutics (AGLE) Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 DeficiencyAeglea BioTherapeutics (AGLE) Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency
www.streetinsider.com - March 15 at 5:38 PM
Aeglea Bio Therapeutics (AGLE) Price Target Increased to $12.00 by Analysts at Needham & Company LLCAeglea Bio Therapeutics (AGLE) Price Target Increased to $12.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - March 14 at 10:16 PM
Head to Head Comparison: Aeglea Bio Therapeutics (AGLE) and Ultragenyx Pharmaceutical (RARE)Head to Head Comparison: Aeglea Bio Therapeutics (AGLE) and Ultragenyx Pharmaceutical (RARE)
www.americanbankingnews.com - March 14 at 9:29 PM
BMO Capital Markets Trims Aeglea Bio Therapeutics (AGLE) Target Price to $18.00BMO Capital Markets Trims Aeglea Bio Therapeutics (AGLE) Target Price to $18.00
www.americanbankingnews.com - March 14 at 3:15 PM
Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial ResultsAeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results
finance.yahoo.com - March 13 at 8:58 AM
BRIEF-Aeglea Bio Says ‍Dosing Of First Uveal And Cutaneous Melanoma Patients With Pegzilarginase In Open-Label Phase 1 Cohort ExpansionsBRIEF-Aeglea Bio Says ‍Dosing Of First Uveal And Cutaneous Melanoma Patients With Pegzilarginase In Open-Label Phase 1 Cohort Expansions
www.reuters.com - March 8 at 8:56 AM
Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with PegzilarginaseAeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase
finance.yahoo.com - March 8 at 8:56 AM
Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic DisordersAeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders
finance.yahoo.com - March 6 at 5:19 PM
Aeglea Bio Therapeutics Inc (AGLE) Expected to Announce Earnings of -$0.55 Per ShareAeglea Bio Therapeutics Inc (AGLE) Expected to Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - March 2 at 12:22 PM
 Aeglea Bio Therapeutics Inc (AGLE) Given $24.00 Consensus Target Price by Brokerages Aeglea Bio Therapeutics Inc (AGLE) Given $24.00 Consensus Target Price by Brokerages
www.americanbankingnews.com - February 26 at 3:20 PM
 Brokerages Set $24.00 Price Target for Aeglea Bio Therapeutics Inc (AGLE) Brokerages Set $24.00 Price Target for Aeglea Bio Therapeutics Inc (AGLE)
www.americanbankingnews.com - February 18 at 11:24 PM
Zacks: Aeglea Bio Therapeutics Inc (AGLE) Receives Average Recommendation of "Strong Buy" from AnalystsZacks: Aeglea Bio Therapeutics Inc (AGLE) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - February 10 at 3:12 PM
 Aeglea Bio Therapeutics Inc (AGLE) Receives Average Recommendation of "Strong Buy" from Brokerages Aeglea Bio Therapeutics Inc (AGLE) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 7 at 11:42 PM
 Aeglea Bio Therapeutics Inc (AGLE) Receives Average Rating of "Strong Buy" from Brokerages Aeglea Bio Therapeutics Inc (AGLE) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 21 at 5:26 AM
Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism ConferenceAeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference
finance.yahoo.com - January 18 at 7:02 PM
 Aeglea Bio Therapeutics Inc (AGLE) Given Consensus Recommendation of "Strong Buy" by Brokerages Aeglea Bio Therapeutics Inc (AGLE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 5 at 7:24 PM
ETFs with exposure to Aeglea Biotherapeutics, Inc. : December 28, 2017ETFs with exposure to Aeglea Biotherapeutics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:11 PM
Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:02 PM
Head-To-Head Review: Aeglea Bio Therapeutics (AGLE) & Its CompetitorsHead-To-Head Review: Aeglea Bio Therapeutics (AGLE) & Its Competitors
www.americanbankingnews.com - December 15 at 5:30 AM
Has Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Got Enough Cash To Cover Its Short-Term Obligations?Has Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Got Enough Cash To Cover Its Short-Term Obligations?
finance.yahoo.com - December 14 at 11:40 AM

SEC Filings

Aeglea Bio Therapeutics (NASDAQ:AGLE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aeglea Bio Therapeutics (NASDAQ:AGLE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aeglea Bio Therapeutics (NASDAQ AGLE) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.